Follow
Ziyang Yu
Ziyang Yu
FOG Pharmaceuticals
Verified email at constellationpharma.com
Title
Cited by
Cited by
Year
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
X Yuan, C Cai, S Chen, Z Yu, SP Balk
Oncogene 33 (22), 2815-2825, 2014
3782014
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer
Z Yu, S Chen, AG Sowalsky, OS Voznesensky, EA Mostaghel, PS Nelson, ...
Clinical cancer research 20 (6), 1590-1600, 2014
2272014
Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity
C Cai, HH He, S Gao, S Chen, Z Yu, Y Gao, S Chen, MW Chen, J Zhang, ...
Cell reports 9 (5), 1618-1627, 2014
1392014
Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells
M Wu, C Min, X Wang, Z Yu, KH Kirsch, PC Trackman, GE Sonenshein
Cancer research 67 (13), 6278-6285, 2007
1052007
Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1–dependent repression of BMP-5
M Romagnoli, K Belguise, Z Yu, X Wang, E Landesman-Bollag, ...
Cancer research 72 (23), 6268-6278, 2012
1032012
Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor
Z Yu, C Cai, S Gao, NI Simon, HC Shen, SP Balk
Clinical cancer research 20 (15), 4075-4085, 2014
1022014
RelB NF-κB represses estrogen receptor α expression via induction of the zinc finger protein Blimp1
X Wang, K Belguise, CF O'Neill, N Sánchez-Morgan, M Romagnoli, ...
Molecular and cellular biology 29 (14), 3832-3844, 2009
932009
A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer
C Min, Z Yu, KH Kirsch, Y Zhao, SR Vora, PC Trackman, DB Spicer, ...
Cancer research 69 (16), 6685-6693, 2009
682009
ErbB2 signaling increases androgen receptor expression in abiraterone-resistant prostate cancer
S Gao, H Ye, S Gerrin, H Wang, A Sharma, S Chen, A Patnaik, ...
Clinical Cancer Research 22 (14), 3672-3682, 2016
482016
Selective androgen receptor modulator RAD140 inhibits the growth of androgen/estrogen receptor–positive breast cancer models with a distinct mechanism of action
Z Yu, S He, D Wang, HK Patel, CP Miller, JL Brown, G Hattersley, ...
Clinical Cancer Research 23 (24), 7608-7620, 2017
392017
Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide
Z Yu, S Sato, PC Trackman, KH Kirsch, GE Sonenshein
PloS one 7 (3), e33287, 2012
352012
A first-in-human phase 1 study of a novel selective androgen receptor modulator (sarm), rad140, in er+/her2-metastatic breast cancer
P LoRusso, E Hamilton, C Ma, N Vidula, RG Bagley, S Troy, M Annett, ...
Clinical breast cancer 22 (1), 67-77, 2022
172022
Ar+ breast cancer treatment methods
G Hattersley, S Jamal, YU Ziyang, C Miller, T Bihani
US Patent App. 15/628,559, 2017
102017
Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC)
E Hamilton, N Vidula, C Ma, P LoRusso, RG Bagley, Z Yu, M Annett, ...
Annals of Oncology 30, v123, 2019
52019
Abstract P5-05-01: Novel mechanisms of action of selective androgen receptor modulator RAD140 in AR+/ER+ breast cancer models
S He, MG Conlan, H Arlt, C Morris, Z Yu
Cancer Research 80 (4_Supplement), P5-05-01-P5-05-01, 2020
22020
Ar+ breast cancer treatment methods
G Hattersley, S Jamal, YU Ziyang, C Miller, T Bihani
12022
Abstract P5-11-01: Phase 1 dose escalation study of a novel selective androgen receptor modulator (SARM), RAD140, in estrogen receptor positive (ER+), human epidermal growth …
E Hamilton, P LoRusso, C Ma, N Vidula, RG Bagley, S Troy, M Annett, ...
Cancer Research 80 (4_Supplement), P5-11-01-P5-11-01, 2020
12020
Phase 1 dose escalation study of a novel selective androgen receptor modulator (SARM), RAD140, in estrogen receptor positive (ER plus), human epidermal growth factor receptor 2 …
E Hamilton, P LoRusso, C Ma, N Vidula, RG Bagley, S Troy, M Annett, ...
CANCER RESEARCH 80 (4), 2020
12020
Abstract P4-13-02: Selective androgen receptor modulator RAD140 inhibits the growth of endocrine-resistant breast cancer models with defined genetic backgrounds
Z Yu, S He, C Miller, J Saeh, G Hattersley, A O'Neill
Cancer Research 79 (4_Supplement), P4-13-02-P4-13-02, 2019
12019
Selective androgen receptor modulator RAD140 inhibits the growth of endocrine-resistant breast cancer models with defined genetic backgrounds
Z Yu, S He, C Miller, J Saeh, G Hattersley, A O'Neill
CANCER RESEARCH 79 (4), 2019
12019
The system can't perform the operation now. Try again later.
Articles 1–20